Go back to trials list
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Description
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Trial Eligibility
Inclusion Criteria: * Pathologically confirmed high-risk recurrent/relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL), after non-response to or failure of first-line standard therapy prior to a definitive therapy e.g.high-dose chemotherapy/autologous stem cell transplant (HDCT/ASCT) * Participants with pathologically confirmed R/R NHL after failure or non-response to second line therapy, including but not limited to primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), mediastinal gray zone lymphoma (MGZL), anaplastic large cell lymphoma (ALCL), or peripheral T-cell lymphoma (PTCL). * Participants must have measurable PET positive disease in both cHL and NHL cohorts. Exclusion Criteria: * Aggressive B-cell lymphomas subtypes including Burkitt lymphoma (BL), lymphoblastic lymphoma, and NK/T-cell lymphoma/leukemia. * Primary CNS lymphoma of the brain or spinal cord, and secondary CNS lymphoma (ie, from systemic non-Hodgkin lymphoma) involving the brain, spinal cord, or with leptomeningeal seeding. * Prior treatment with an anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, with the exception of anti-PD(L)-1 targeted therapies * Prior treatment with lymphocyte activation gene-3 (LAG-3)-targeted agents * Prior autologous stem cell transplantation (HDCT/ASCT) * History of allogeneic bone marrow transplantation. Other protocol-defined inclusion/exclusion criteria apply
Study Info
Organization
Bristol-Myers Squibb
Primary Outcome
Incidence of dose-limiting toxicities (DLTs)
Interventions
Locations Recruiting
Phoenix Childrens Hospital PCH - Phoenix Childrens Medical Group - Hematology Oncology
United States, Arizona, Phoenix
Lucile Packard Childrens Hospital - Stanford University
United States, California, Palo Alto
Yale University
United States, Connecticut, New Haven
Local Institution - 0061
United States, Delaware, Wilmington
Golisano Children's Hospital of Southwest Florida
United States, Florida, Fort Myers
Interested in joining this trial?
Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.
Get the latest thought leadership on your B-Cell Lymphoma delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.